Search

Maravai LifeSciences Holdings Inc (Class A)

Fechado

SetorSaúde

5.65 -2.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.54

Máximo

5.77

Indicadores-chave

By Trading Economics

Rendimento

-21M

-24M

Vendas

-14M

51M

EPS

-0.07

Margem de lucro

-47.189

Funcionários

435

EBITDA

-17M

-5.2M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+25.43% upside

Dividendos

By Acuity

Próximos Ganhos

5 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-120M

2.2B

Abertura anterior

7.9

Fecho anterior

5.65

Sentimento de Notícias

By Acuity

100%

0%

329 / 340 Ranking em Healthcare

Maravai LifeSciences Holdings Inc (Class A) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de ago. de 2026, 19:16 UTC

Maravai LifeSciences Holdings Inc. shares are lower, retracing from earlier gains amid broader market concerns over a decline in U.S. retail sales.

11 de ago. de 2026, 20:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, continuing a trend of five consecutive daily declines and trading below the 20-day moving average.

10 de ago. de 2026, 19:46 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, but shares are trading lower amid mixed analyst ratings and a continuing decline since Friday.

7 de ago. de 2026, 20:02 UTC

News

Maravai LifeSciences shares are lower despite Wells Fargo raising the price target to $6.50 following a revenue increase to $51.4 million in Q2.

6 de ago. de 2026, 23:51 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

3 de ago. de 2026, 19:46 UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

31 de jul. de 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

30 de jul. de 2026, 16:56 UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

29 de jul. de 2026, 20:09 UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

28 de jul. de 2026, 18:06 UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

24 de jul. de 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

23 de jul. de 2026, 09:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

22 de jul. de 2026, 19:56 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

21 de jul. de 2026, 19:56 UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

20 de jul. de 2026, 20:02 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Comparação entre Pares

Variação de preço

Maravai LifeSciences Holdings Inc (Class A) Previsão

Preço-alvo

By TipRanks

25.43% parte superior

Previsão para 12 meses

Média 7.25 USD  25.43%

Máximo 8 USD

Mínimo 6.5 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Maravai LifeSciences Holdings Inc (Class A) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

329 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat